Oppenheimer analyst Francois Brisebois raised the firm’s price target on Mind Medicine to $25 from $22 and reiterates an Outperform rating on the shares. The analyst views the company’s Phase 2b clinical results of MM-120 in generalized anxiety disorder as a best case scenario.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MNMD:
